P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 9, 2010, Pages 1106-1113

  Huynh, Nhi ^a   Liu, Kevin H ^a   Baldwin, Graham S ^a   He, Hong ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

AKT; Colon cancer; ERK; PAK1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE 1; PROTEIN KINASE B; ONCOPROTEIN; P21 ACTIVATED KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CARCINOMA; CELL MOTION; COLON TUMOR; DRUG EFFECTS; GENETICS; HCT116 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; TUMOR INVASION;

CARCINOMA; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; ONCOGENE PROTEIN V-AKT; P21-ACTIVATED KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 77954951627     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.05.007     Document Type: Article

References (30)

1. Calvert P.M., Frucht H. The genetics of colorectal cancer. Ann Intern Med. 2002, 137:603-612.
2. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., Futreal P.A., Stratton M.R., Wooster R., Leung S.Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002, 62:6415.
3. Fransén K., Klintenäs M., Osterström A., Dimberg J., Monstein H.J., Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25(4):527-533. Epub 2003 Dec 19. Click here to read 25 (2004) 527-533.
4. Fang J.Y., Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005, 6:322-327.
5. Repasky G.A., Chenette E.J., Der C.J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol 2004, 14:639-647.
6. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
7. Parsons D.W., Wang T.L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., Velculescu V.E. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436:792.
8. Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., Schwartz S., Duval A., Carneiro F., Machado J.C., Hamelin R., Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005, 41:1649-1654.
9. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
10. Balmanno K., Chell S.D., Gillings A.S., Hayat S., Cook S.J. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009.
11. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
12. Bokoch G.M. Biology of the p21-activated kinases. Annu Rev Biochem 2003, 72:743-781.
13. Bagheri-Yarmand R., Mandal M., Taludker A.H., Wang R.A., Vadlamudi R.K., Kung H.J., Kumar R. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem 2001, 276:29403-29409.
14. Bagheri-Yarmand R., Vadlamudi R.K., Wang R.A., Mendelsohn J., Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 2000, 275:39451-39457.
15. Carter J.H., Douglass L.E., Deddens J.A., Colligan B.M., Bhatt T.R., Pemberton J.O., Konicek S., Hom J., Marshall M., Graff J.R. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004, 10:3448-3456.
16. King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., Marshall M.S. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 1998, 396:180-183.
17. Slack-Davis J.K., Eblen S.T., Zecevic M., Boerner S.A., Tarcsafalvi A., Diaz H.B., Marshall M.S., Weber M.J., Parsons J.T., Catling A.D. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 2003, 162:281-291.
18. Mao K., Kobayashi S., Jaffer Z.M., Huang Y., Volden P., Chernoff J., Liang Q. Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes. J Mol Cell Cardiol 2008, 44:429-434.
19. Higuchi M., Onishi K., Kikuchi C., Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol 2008, 10:1356-1364.
20. Dummler B., Ohshiro K., Kumar R., Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009, 28:51-63.
21. Ishizu K., Sunose N., Yamazaki K., Tsuruo T., Sadahiro S., Makuuchi H., Yamori T. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull 2007, 30:1779-1783.
22. Gessi S., Merighi S., Varani K., Cattabriga E., Benini A., Mirandola P., Leung E., Mac Lennan S., Feo C., Baraldi S., Borea P.A. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol 2007, 211:826-836.
23. Samuels Y., Diaz L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573.
24. Wendt M.K., Drury L.J., Vongsa R.A., Dwinell M.B. Constitutive CXCL12 expression induces anoikis in colorectal carcinoma cells. Gastroenterology 2008, 135:508-517.
25. Yu L.F., Wang J., Zou B., Lin M.C., Wu Y.L., Xia H.H., Sun Y.W., Gu Q., He H., Lam S.K., Kung H.F., Wong B.C. XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer. Cancer 2007, 109:1996-2003.
26. Kumar H., Heer K., Lee P.W., Duthie G.S., MacDonald A.W., Greenman J., Kerin M.J., Monson J.R. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998, 4:1279-1285.
27. Tokunaga T., Oshika Y., Abe Y., Ozeki Y., Sadahiro S., Kijima H., Tsuchida T., Yamazaki H., Ueyama Y., Tamaoki N., Nakamura M. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998, 77:998-1002.
28. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., Mori A., Onodera H., Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998, 78:1379-1384.
29. Ellis L.M., Takahashi Y., Liu W., Shaheen R.M. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000, 5(Suppl 1):11-15.
30. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.